News & Updates
Filter by Specialty:
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
A multimodal intervention applied in general practice results in a significant decrease in antibiotic prescribing and an increase in guideline adherence among women with uncomplicated urinary tract infection (UTI), a study has shown.
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
13 Nov 2023
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
Treatment with pyrotinib in combination with trastuzumab and docetaxel (tras/doc) results in longer progression-free survival (PFS) than placebo combined with tras/doc in patients with untreated HER2-positive metastatic breast cancer, a study has shown. In addition, the safely profile of tras/doc plus pyrotinib is manageable.
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
10 Nov 2023
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
08 Nov 2023
Neoadjuvant immunotherapy delivers better response in NSCLC
Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.